Detalles de la búsqueda
1.
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
Br J Cancer
; 130(4): 613-619, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38182687
2.
Effectiveness of a nurse-led telephone follow-up in the therapeutic management of patients receiving oral antineoplastic agents: a randomized, multicenter controlled trial (ETICCO study).
Support Care Cancer
; 29(8): 4257-4267, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33409726
3.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet
; 393(10191): 2591-2598, 2019 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31178155
4.
Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP).
Blood
; 132(7): 707-716, 2018 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29980524
5.
Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial.
Support Care Cancer
; 27(5): 1879-1889, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30194492
6.
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Breast Cancer Res
; 19(1): 98, 2017 Aug 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-28830573
7.
Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience.
Chemotherapy
; 61(3): 122-6, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26752402
8.
[Perception of adverse reactions of chemotherapy and hormone therapy by women treated for breast cancer]. / Perception des effets indésirables de la chimiothérapie et de l'hormonothérapie par les femmes prises en charge pour un cancer du sein.
Therapie
; 71(3): 263-73, 2016 Jun.
Artículo
en Francés
| MEDLINE | ID: mdl-27235649
9.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Lancet Oncol
; 14(8): 741-8, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23764181
10.
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients.
Breast Cancer
; 30(2): 315-328, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36602669
11.
Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials.
Breast Cancer Res Treat
; 134(3): 903-13, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22270929
12.
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
J Clin Oncol
; 40(32): 3699-3708, 2022 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35605174
13.
TTF-1-positive Metastatic Endometrioid Carcinoma: A Case Report and Review of Literature of a Potential Diagnostic Pitfall.
Appl Immunohistochem Mol Morphol
; 28(1): e6-e9, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28777147
14.
Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study.
Breast
; 49: 1-7, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31670262
15.
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer.
Sci Rep
; 10(1): 10757, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32612272
16.
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).
Breast
; 49: 132-140, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31790959
17.
[LHRH analogs in adjuvant endocrine therapy for pre-menopausal localized breast cancers: Ending the controversy for novel guidelines?] / Analogues de la LH-RH dans le traitement hormonal adjuvant dans les cancers du sein localisés de la femme pré-ménopausée : la fin d'une controverse pour de nouvelles recommandations ?
Bull Cancer
; 106(4): 342-353, 2019 Apr.
Artículo
en Francés
| MEDLINE | ID: mdl-30853114
18.
Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
Eur J Cancer
; 118: 156-165, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31351267
19.
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
Eur J Cancer
; 81: 151-160, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28624696
20.
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.
NPJ Breast Cancer
; 3: 4, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28649644